Literature DB >> 21118924

Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial.

Mari Luntamo1, Teija Kulmala, Bernard Mbewe, Yin Bun Cheung, Kenneth Maleta, Per Ashorn.   

Abstract

Preterm delivery, which is associated with infections during pregnancy, is common in sub-Saharan Africa. We enrolled 1,320 pregnant women into a randomized, controlled trial in Malawi to study whether preterm delivery and low birth weight (LBW) incidence can be reduced by intermittent preventive treatment of maternal malaria and reproductive tract infections. The participants received either sulfadoxine-pyrimethamine (SP) twice (controls), monthly SP, or monthly SP and two doses of azithromycin (AZI-SP). The incidence of preterm delivery was 17.9% in controls, 15.4% in the monthly SP group (P = 0.32), and 11.8% in AZI-SP group (risk ratio = 0.66, P = 0.01). Compared with controls, those in AZI-SP group had a risk ratio of 0.61 (P = 0.02) for LBW. Incidence of serious adverse events was low in all groups. In conclusion, the incidence of preterm delivery and LBW can in some conditions be reduced by treating pregnant women with monthly SP and two azithromycin doses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118924      PMCID: PMC2990034          DOI: 10.4269/ajtmh.2010.10-0264

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  40 in total

1.  Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi.

Authors:  Scott J Filler; Peter Kazembe; Michael Thigpen; Alan Macheso; Monica E Parise; Robert D Newman; Richard W Steketee; Mary Hamel
Journal:  J Infect Dis       Date:  2006-06-20       Impact factor: 5.226

2.  Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99.

Authors:  S J Rogerson; E Chaluluka; M Kanjala; P Mkundika; C Mhango; M E Molyneux
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

3.  Determinants of linear growth and predictors of severe stunting during infancy in rural Malawi.

Authors:  M Espo; T Kulmala; K Maleta; T Cullinan; M L Salin; P Ashorn
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

4.  Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.

Authors:  M E Parise; J G Ayisi; B L Nahlen; L J Schultz; J M Roberts; A Misore; R Muga; A J Oloo; R W Steketee
Journal:  Am J Trop Med Hyg       Date:  1998-11       Impact factor: 2.345

5.  Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers.

Authors:  S L Anderson; J Berman; R Kuschner; D Wesche; A Magill; B Wellde; I Schneider; M Dunne; B G Schuster
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

6.  The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.

Authors:  L J Schultz; R W Steketee; A Macheso; P Kazembe; L Chitsulo; J J Wirima
Journal:  Am J Trop Med Hyg       Date:  1994-11       Impact factor: 2.345

7.  Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.

Authors:  Standwell Nkhoma; Malcolm Molyneux; Stephen Ward
Journal:  Acta Trop       Date:  2007-04-24       Impact factor: 3.112

Review 8.  Intermittent presumptive treatment for malaria.

Authors:  Nicholas J White
Journal:  PLoS Med       Date:  2005-01       Impact factor: 11.069

Review 9.  Maternal and child undernutrition: consequences for adult health and human capital.

Authors:  Cesar G Victora; Linda Adair; Caroline Fall; Pedro C Hallal; Reynaldo Martorell; Linda Richter; Harshpal Singh Sachdev
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

10.  A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women.

Authors:  Linda Kalilani; Innocent Mofolo; Marjorie Chaponda; Stephen J Rogerson; Alisa P Alker; Jesse J Kwiek; Steven R Meshnick
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

View more
  50 in total

1.  Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches.

Authors:  Eric H Ekland; Jessica Schneider; David A Fidock
Journal:  FASEB J       Date:  2011-07-11       Impact factor: 5.191

2.  Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.

Authors:  Steve M Taylor; Alejandro L Antonia; Ebbie Chaluluka; Victor Mwapasa; Gaoqian Feng; Malcolm E Molyneux; Feiko O ter Kuile; Steven R Meshnick; Stephen J Rogerson
Journal:  Clin Infect Dis       Date:  2012-03-22       Impact factor: 9.079

Review 3.  Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review.

Authors:  D L Joseph Davey; H I Shull; J D Billings; D Wang; K Adachi; J D Klausner
Journal:  Sex Transm Dis       Date:  2016-07       Impact factor: 2.830

4.  Malaria elimination in Malawi: research needs in highly endemic, poverty-stricken contexts.

Authors:  Mark L Wilson; Edward D Walker; Themba Mzilahowa; Don P Mathanga; Terrie E Taylor
Journal:  Acta Trop       Date:  2011-11-15       Impact factor: 3.112

5.  Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.

Authors:  Sam Salman; Francisca Baiwog; Madhu Page-Sharp; Susan Griffin; Harin A Karunajeewa; Ivo Mueller; Stephen J Rogerson; Peter M Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Azithromycin-containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in Papua New Guinea - an exploratory analysis.

Authors:  Holger W Unger; Regina A Wangnapi; Maria Ome-Kaius; Philippe Boeuf; Stephan Karl; Ivo Mueller; Stephen J Rogerson
Journal:  Matern Child Nutr       Date:  2015-09-15       Impact factor: 3.092

7.  A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.

Authors:  Brioni R Moore; John M Benjamin; Roselyn Tobe; Maria Ome-Kaius; Gumul Yadi; Bernadine Kasian; Charles Kong; Leanne J Robinson; Moses Laman; Ivo Mueller; Stephen Rogerson; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

8.  The World Health Organization's global target for reducing childhood stunting by 2025: rationale and proposed actions.

Authors:  Mercedes de Onis; Kathryn G Dewey; Elaine Borghi; Adelheid W Onyango; Monika Blössner; Bernadette Daelmans; Ellen Piwoz; Francesco Branca
Journal:  Matern Child Nutr       Date:  2013-09       Impact factor: 3.092

9.  Comparison of real-time PCR and microscopy for malaria parasite detection in Malawian pregnant women.

Authors:  Anne-Maria Rantala; Steve M Taylor; Paul A Trottman; Mari Luntamo; Bernard Mbewe; Kenneth Maleta; Teija Kulmala; Per Ashorn; Steven R Meshnick
Journal:  Malar J       Date:  2010-10-06       Impact factor: 2.979

Review 10.  Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis.

Authors:  Kassoum Kayentao; Paul Garner; Anne Maria van Eijk; Inbarani Naidoo; Cally Roper; Abdunoor Mulokozi; John R MacArthur; Mari Luntamo; Per Ashorn; Ogobara K Doumbo; Feiko O ter Kuile
Journal:  JAMA       Date:  2013-02-13       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.